Hong Liang Xie

US Patent:

6963544, Nov 8, 2005

Filed:

Aug 31, 2000

Appl. No.:

09/651717

Inventors:

Krishna Balachandran - Middletown NJ, US
Cristian Demetrescu - Twickenham, GB
Richard Paul Ejzak - Wheaton IL, US
Sanjiv Nanda - Clarksburg NJ, US
Hong Xie - Downers Grove IL, US

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

H04J001/08

US Classification:

370281, 370295, 370330, 370343, 370436, 370478, 370480, 370498

Abstract:

A system for providing statistical multiplexing of speech, other real-time data services and non-real-time data services for point to point and point to multipoint communications. The system has fast access and assignment procedures that allow the multiplexing of real-time, delay-critical data services with non-real-time data services. Continuity of periodic control channels across speech talkspurt and silence periods for conversational voice is maintained to carry signal measurement reports, channel quality feedback, and “comfort” noise information between different parts of the system.

US Patent:

20200384006, Dec 10, 2020

Filed:

Jun 5, 2020

Appl. No.:

16/893477

Inventors:

- Beerse, BE
Kathryn Elizabeth Packman - Newton MA, US
Nahor Haddish-Berhane - Doylestown PA, US
Geert S.J. Mannens - Lier, BE
Junguo Zhou - Flemington NJ, US
Anthony T. Greway - Bound Brook NJ, US
Dirk Brehmer - Freiburg, DE
Yue Guo - North Wales PA, US
Tongfei Wu - Hever, BE
Hong Xie - Dresher PA, US
Josh Lauring - Towson MD, US

International Classification:

A61K 31/7064
A61P 35/04

Abstract:

The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.